Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CLpro targeting repurposed drug candidates
Abstract Background Severe acute respiratory syndrome (SARS) has been initiating pandemics since the beginning of the century. In December 2019, the world was hit again by a devastating SARS episode that has so far infected almost four million individuals worldwide, with over 200,000 fatalities havi...
Main Authors: | Nitin Chitranshi, Vivek K. Gupta, Rashi Rajput, Angela Godinez, Kanishka Pushpitha, Ting Shen, Mehdi Mirzaei, Yuyi You, Devaraj Basavarajappa, Veer Gupta, Stuart L. Graham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://link.springer.com/article/10.1186/s12967-020-02448-z |
Similar Items
-
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
by: Rajaiah Alexpandi, et al.
Published: (2020-07-01) -
Glaucoma is associated with plasmin proteolytic activation mediated through oxidative inactivation of neuroserpin
by: Vivek Gupta, et al.
Published: (2017-08-01) -
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19
by: Mohammad Azam Ansari, et al.
Published: (2020-11-01) -
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
by: Shivani Kumar, et al.
Published: (2017-10-01) -
Molecular determinants and interaction data of cyclic peptide inhibitor with the extracellular domain of TrkB receptor
by: Nitin Chitranshi, et al.
Published: (2016-03-01)